Combo immunotherapy may herald new standard of care for kidney cancer

Kidney Cancer UK has previously described the potential of combining different immunotherapy drugs for the treatment of advanced kidney cancer. Following the use of nivolumab (Opdivo) as a second-line drug within the NHS since last November. Today there has been more positive news about immunotherapy combination trials in America. We are also aware that there may be immunotherapy combination trials launching in the UK very soon.